Drug intelligence / Profile preview

7228

Development stage: Preclinical
Lead developer: Guerbet
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

7228 is a novel Ultrasmall Particle of Iron Oxide (USPIO) developed by GUERBET. It functions as an MR imaging contrast agent, specifically designed to visualize atherosclerotic plaques. Preclinical studies in hyperlipidemic rabbits have shown that 7228 is taken up by macrophages within these plaques, leading to detectable susceptibility effects in MR imaging, and demonstrating its potential for functional characterization of plaque activity.

Beyond the preview

Go deeper on 7228.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7228.

Explore the full profile